Medtronic's Hugo RAS System Receives FDA Approval for Urological Minimally Invasive Surgeries

Source: MedRobot

Reprint Requirements: You can directly repost, but please credit the source at the beginning of the article.

 # Product Introduction

Hugo Surgical Robot is a multi-quadrant modular robotic system developed by Medtronic in the field of soft tissue surgery, first released in 2019. The system consists ofSurgeon Console, Robotic Arm Cart, Imaging Tower and Visualization Systemand other parts, which can be flexibly configured according to the needs of the surgical procedure, suitable for various soft tissue surgery scenarios such as urology, gynecology, and general surgery.

The console adopts3D High-Resolution Display, and cooperate with wrist-joint-style operating instruments to achieve flexibility in delicate operations. The doctor operates through the master control end, and the system transmits the movements in real time to the robotic arm end effector for execution.
Imaging Configuration3D High-Definition Optical System, and can integrate near-infrared fluorescence imaging (ICG) function for blood flow and tissue perfusion assessment.

At the digital level, the Hugo platform and Medtronic's Touch Surgery Enterprise Connected to the system, it enables real-time acquisition, storage, and analysis of surgical videos, providing data support for intraoperative training, postoperative review, and multi-center collaboration.

Hugo's design concept is based onOpen ArchitectureAndScalability`, leaving interfaces for further integration with imaging systems, data platforms, and AI tools in the future.`

Hugo RAS not only supports urology but is also expanding its indications to include hernia repair, gynecology, general soft tissue surgery, and more, to cover a wider range of minimally invasive surgical scenarios. Medtronic has launched clinical and commercial applications of Hugo in over 30 countries across five continents globally.

# Registration and Clinical Data (U.S.)

The FDA approval of Hugo RAS is based on its multicenter prospective study conducted in the United States. Expand URO (IDE)The results. A total of137 patients,Covering common urological surgery types such as prostatectomy, nephrectomy, and cystectomy. During the trialHugo demonstrated a 98.5% surgical success rate (i.e., no conversion to other surgical methods), far exceeding the preset benchmark of 85%. 

In terms of safety, the incidence of severe complications graded III or higher within 30 days post-surgery was low, with rates of 3.7% in the prostatectomy group, 1.9% in the nephrectomy group, and 17.9% in the cystectomy group, all below the preset safety threshold. Both the conversion rate and the incidence of severe complications were within acceptable ranges.

Following approval in the United States, Medtronic has also completed IDE clinical studies for other indications, such as hernia repair, achieving safety and efficacy endpoints, laying the groundwork for expanding into more surgical procedures in the future.

# Market and Strategic Significance

For Medtronic, the FDA approval of Hugo RAS marks a key milestone in its robotic surgery strategy. The system offers hospitals a new, flexible option for robotic surgery, breaking the long-standing market dominance of a single mainstream system.

According to public data, the number of urological surgeries (prostate, kidney, bladder) performed annually in the U.S. alone reaches approximately 230,000 cases. The approval of Hugo covers these high-frequency procedures, indicating a huge potential market size.

The modular design, flexible deployment, and digital ecosystem (training + remote guidance + data review) of the system can help hospitals lower the acquisition and usage barriers, increase OR (operating room) utilization and return on investment, which is highly attractive to hospitals with limited resources or high surgical volumes.

At the same time, Hugo's multi-indication development pathway(Urinary → Hernia Repair → Gynecology → Soft Tissue)Showcases Medtronic's ambition to create a "universal soft tissue robotic platform" — positioning it as a mainstream robotic system covering a wide range of surgical types.

For patients, the launch of Hugo means that more hospitals will have the capability to perform robotic surgeries, especially in small and medium-sized hospitals / regional hospitals. This is expected to improve the accessibility of minimally invasive surgeries, reduce waiting times, and enhance treatment coverage and equity.